Labetalol
- Generic Name
- Labetalol
- Brand Names
- Trandate
- Drug Type
- Small Molecule
- Chemical Formula
- C19H24N2O3
- CAS Number
- 36894-69-6
- Unique Ingredient Identifier
- R5H8897N95
- Background
Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.
Labetalol was granted FDA approval on 1 August 1984.
- Indication
Labetalol injections are indicated to control blood pressure in severe hypertension. Labetalol tablets are indicated alone or in combination with antihypertensives like thiazides and loop diuretics to manage hypertension.
- Associated Conditions
- Chronic Stable Angina Pectoris, Hypertension, Hypertensive Emergency, Hypertensive crisis, Pheochromocytoma, Subarachnoid Hemorrhage
- Associated Therapies
- -
Intravenous Labetalol vs Phentolamine for the Management of Severe Preeclampsia.
- Conditions
- Interventions
- First Posted Date
- 2024-04-26
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Assiut University
- Target Recruit Count
- 200
- Registration Number
- NCT06385600
The Efficacy of Dexmedetomidine Versus Labetalol In Providing Controlled Hypotension In Dacryocystorhinostomy SurgeryA Comparative Randomized Prospective Study
- Conditions
- Interventions
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-04-04
- Lead Sponsor
- Sohag University
- Target Recruit Count
- 50
- Registration Number
- NCT06346561
- Locations
- 🇪🇬
Sohag University hospitals, Sohag, Egypt
Comparative Study of Intravenous Labetalol Versus Intravenous Nitroglycerin Versus Sublingual Nifedipine
- Conditions
- Interventions
- First Posted Date
- 2024-02-20
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- Sohag University
- Target Recruit Count
- 60
- Registration Number
- NCT06265415
Hypotensive Anesthesia for Orthognathic Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-10-23
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Boston Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT06093893
- Locations
- 🇺🇸
Boston Medical Center, Boston, Massachusetts, United States
Treatment of Elevated Blood Pressures in Early Pregnancy
- Conditions
- Interventions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Marshall University
- Target Recruit Count
- 2
- Registration Number
- NCT05955040
- Locations
- 🇺🇸
Marshall Obstetrics and Gynecology, Huntington, West Virginia, United States
Postpartum Hypertension Study
- Conditions
- Interventions
- First Posted Date
- 2021-12-01
- Last Posted Date
- 2024-03-18
- Lead Sponsor
- Columbia University
- Target Recruit Count
- 104
- Registration Number
- NCT05139238
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
Effect of Labetalol, Atenolol, and Nifedipine on Maternal Hemodynamics Measured by ICG in Early Pregnancy
- First Posted Date
- 2021-02-16
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Marshall University
- Target Recruit Count
- 60
- Registration Number
- NCT04755764
- Locations
- 🇺🇸
Maternal Hypertension Center at Cabell Huntington Hospital, Huntington, West Virginia, United States
Evaluation of Intravenous Infusion of Labetalol Versus Magnesium Sulfate
- Conditions
- Interventions
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2022-11-15
- Lead Sponsor
- Zagazig University
- Target Recruit Count
- 60
- Registration Number
- NCT04539379
- Locations
- 🇪🇬
Faculty of Medicine,Zagazig University, Zagazig, Zagazig, Elsharkia,egypt, Egypt
Blood Pressure Management in Stroke Following Endovascular Treatment
- Conditions
- Interventions
- First Posted Date
- 2020-07-23
- Last Posted Date
- 2023-11-07
- Lead Sponsor
- Hamilton Health Sciences Corporation
- Target Recruit Count
- 30
- Registration Number
- NCT04484350
- Locations
- 🇨🇦
Hamilton General Hospital, Hamilton, Ontario, Canada
Postpartum Management of Gestational Hypertensive Disorders Using Furosemide
- Conditions
- Interventions
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Wright State University
- Target Recruit Count
- 13
- Registration Number
- NCT04343235
- Locations
- 🇺🇸
Miami Valley Hospital, Dayton, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.